Divalproex Sodium
Product Images NDC 68071-2717

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68071-2717). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp (68071 2717 6)

Pdp (68071 2717 6)
This is the packaging information of Divalproex Sodium 250mg tablets. It includes details like lot number, manufacturer's NDC and expiry date. The tablets are oval-shaped peach-colored and imprinted with "D85". There is a warning to keep the medicine out of reach of children and to store it at controlled temperature. The information also advises to call a doctor for medical advice about any side effects of the medicine and to report them to the FDA.*
FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
FDA Label Image

Figure 3 (Divalproex Fig3)

Figure 3 (Divalproex Fig3)
This text appears to be a figure caption for a graph or chart. The figure, labeled as "Figure 3", shows the relationship between two variables, "High Dose" and "Low Dose", with regard to a "Reduction In CPS Rate". The data is displayed in a bar graph format, with a vertical axis labeled as "% of Patients" and a horizontal axis showing "Improvement", "No Change", and "Worsening". Unfortunately, without the actual graph or chart, it is difficult to provide further information or analysis.*
FDA Label Image

Figure 4 (Divalproex Fig4)

Figure 4 (Divalproex Fig4)
The text provides information on migraine rates in two studies using a placebo and Divalproex Sodium Delayed-Release Tablets. Study 1 had a mean dose of 1,087 mg/day, while Study 2 had a dose of 500 or 1,000 mg/day. The mean 4-week migraine rates are not mentioned.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.